Alzheimer Disease Clinical Trial
Official title:
Palliative Care Telehealth Delivered Program of SUPPORT-D Intervention for Persons With Alzheimer's Disease and Caregivers Phase 2
Verified date | April 2024 |
Source | Medical University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research is pilot test a nurse led intervention previously used in patients with pulmonary fibrosis and their caregivers in a new population (persons living with Mild Cognitive Impairment or Alzheimer's disease and their caregivers. The researchers hypothesize improving advanced care planning in this population will result in enhanced quality of life over illness trajectory and improve safety for community dwelling PWD/CG dyads. Findings from this study will inform additional necessary adaptations required prior to conducting larger scale powered randomized control trial.
Status | Completed |
Enrollment | 58 |
Est. completion date | April 1, 2024 |
Est. primary completion date | April 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: The participants in this study include persons with Alzheimer's disease (PWD) and their caregivers (CG. - Persons with Alzheimer's Disease (investigators anticipate cognitive impairment within this group) - 18 years old or older - Diagnosis of Alzheimer's Disease or suspected Alzheimer's disease (FAST score < 4) - Able to read and speak English (intervention in English) Caregivers (CG) - > 18 years old - Non-paid (eliminates professional caregivers) - Provides care to someone living with Alzheimer's Disease or suspected Alzheimer's disease (self-report) - Able to read and speak English (written materials in English) - No diagnosis of cognitive impairment Exclusion Criteria: - Inability or unwillingness to provide informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | National Center for Advancing Translational Sciences (NCATS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Alzheimer's Disease Knowledge Scale (ADKS) score | 30 items (T/F) summed total of correct items higher score indicates higher knowledge (scores range from 0-30) | baseline, at study completion, an average of 8 weeks | |
Primary | Acceptability of Intervention Measure (AIM) score | 4 items (5 point Likert scale) average score across items higher score indicates more acceptability of intervention (raw score ranges from 4-20) | at study completion, an average of 8 weeks | |
Primary | Change in feasibility score | 4 items (5 point Likert scale) average score across items higher score indicates greater feasibility of intervention (raw scores range from 4-20) | at study completion, an average of 8 weeks | |
Primary | Change Zarit caregiver burden score | 12 items (4 point Likert scale) summed score with higher scores indicating greater caregiver distress (raw scores range from 0-48) | baseline, at study completion, an average of 8 weeks | |
Primary | Change in Perceived Stress scale score | 10 items (4 point Likert scale) summed score across items with higher scores indicate greater levels of stress (scores range from 0-40) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Symptom burden physical function score | 4 item scale (5 point Likert scale) Standard t scores with higher scores indicating increased physical function (raw scores range from 4-20) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Symptom burden anxiety score | 4 item scale (4 point Likert scale) Standard t scores with higher scores indicating increased anxiety (raw scores range from 4-20) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Symptom burden depression score | 4 item scale (5 point Likert scale) Standard t scores with higher scores indicating increased depression (raw scores range from 4-20) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Symptom burden fatigue score | 4 item scale (5 point Likert scale) Standard t scores with higher scores indicating increased fatigue (raw scores range from 4-20) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Symptom burden sleep quality score | 4 item scale (5 point Likert scale) Standard t scores with higher scores indicating increased sleep quality (raw scores range from 4-20) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Symptom burden satisfaction with social role score | 4 item scale (5 point Likert scale) Standard t scores with higher scores indicating increased satisfaction with social role (raw scores range from 4-20) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Symptom burden pain score | 4 item scale (5 point Likert scale) Standard t scores with higher scores indicating increased pain (raw scores range from 4-20) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Quality of life-Alzheimer's Disease (QoL-AD) score | 13 items (4 point Likert scale) summed score across items with higher scores indicating better quality of life (scores range from 13-54) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in self-efficacy for caregiving score | 8 items rated from 1-10 mean score across items with higher scores indicating higher self-efficacy (raw scores range from 8-80) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in Safety assessment scale score | 32 items summed score across items with higher scores indicating higher risk for accidents (scores range from 11-47) | baseline and at study completion, an average of 8 weeks | |
Primary | Change in technology literacy score | 21 items (4 point Likert scale) summed scores across items with higher scores indicating better digital health literacy (scores range from 21-84) | baseline and at study completion, an average of 8 weeks | |
Primary | Number of participants completing advance care planning documents | Number of participants who complete advance care planning documents | at study completion, an average of 8 weeks | |
Primary | Appropriateness of Intervention score | 4 items (5 point Likert scale) average score across items higher score indicates greater appropriateness of intervention (scores range from 4-20) | at study completion, an average of 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |